COVID-19 and HIV
Article Sidebar
Main Article Content
Throughout the COVID-19 pandemic, the main risk factors associated with the progression to severe disease or death have been typically advanced age, diabetes mellitus, obesity, high blood pressure, heart disease, and chronic pneumopathy. Because of their immunosuppression status, persons with HIV were also expected to have a higher susceptibility to infection or a poor clinical evolution. So far, this has not been confirmed to happen, giving way to hypotheses about the role of immunosuppression or the use of antiretrovirals, which could explain this paradox. In this article we present the existing data on the epidemiology and characteristics of HIV-COVID-19 co-infection, discuss the available evidence on the possible factors involved in the evolution of individuals affected by both viruses, analyze other determinants that may negatively affect persons with HIV during the pandemic, and present recommendations for the prevention and care of COVID-19 infection in the context of HIV.
- COVID-19
- Pandemics
- HIV-2
- Ritonavir
- Severe Acute Respiratory Syndrome
- Ribavirin
- Coronavirus
- HIV-1
- Protease Inhibitors
- Influenza A virus
- Global Health
- Critical Illness
Juan Carlos Alzate Angel, Corporación para Investigaciones Biológicas.
Doctor with a Master's Degree in Clinical Sciences at the Faculty of Medicine - Universidad de Antioquia, and a Ph.D. student in Epidemiology at the Facultad Nacional de Salud Pública. He is a professor of the Master in Research in Infectious Diseases at the Universidad de Santander and a professor of Clinical Epidemiology - HIV at the Universidad de Antioquia.
Currently, he is the lead investigator of the Corporación para Investigaciones Biológicas's clinical research unit and HIV program.
https://orcid.org/0000-0003-0319-0623
Ernesto Martínez-Buitrago, Universidad del Valle. Cali, Colombia
MD graduated in internal medicine at Universidad del Valle in Cali, Colombia. Shortly after graduating he focused his interests in infectious diseases when he joined the Special Immunology Fellowship Program at the University of Miami, Miami USA for HIV comprehensive training at Jackson Memorial Hospital in Miami. Dr Martínez Buitrago later completed a 2-year clinical fellowship in infectious diseases at the University of Cincinnati.
Upon returning to Colombia, Dr Martínez Buitrago rejoined the Universidad del Valle in Cali as a faculty member in the Department of Internal Medicine, and in the Hospital Universitario del Valle, the largest public hospital in Colombia, and at the Infectious Diseases and Infection Control Unit.
Co-founder as well in 2014 of the HIV Latin American Workshop has worked along with participants from 11 countries in gathering and analyzing relevant information and data from Colombia and the region to characterize the epidemics in LATAM. Dr. Martínez Buitrago convened a large group of Colombian centers of HIV care to create the VIHCOL Group to work in a national level in research of the HIV Colombian epidemic, with data already presented in important Colombian research meetings with outstanding results.
María Paulina Posada-Vergara, Grupo VIHCOL
Physician from the Universidad Nacional de Colombia, Bogotá (1996), she obtained the title of Infectology from the Emilio Ribas Institute of Infectology, Sao Paulo, Brazil, and Master of Science from the University of Sao Paulo, Brazil. He has more than 20 years of experience as a specialist, and focused on the diagnosis and treatment of people with tropical diseases, mycoses, hepatitis, HIV / AIDS, emerging viruses, sexually transmitted diseases, and traveler's medicine. Currently, she is a member of the Colombian Association of Infectology.
Velavan, T.P. and Meyer, C.G. (2020), The COVID‐19 epidemic. Trop Med Int Health, 25: 278-280. https://doi.org/10.1111/tmi.13383
Chan JF, Yuan S, Kok KH et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person‐to‐person transmission: a study of a family cluster. Lancet 2020. S0140-6736(20) 30154-9. https://doi.org/10.1016/S0140-6736(20)30154-9
Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancent, Infectious Diseases 2020. DOI 10.1016/S1473-3099(20)30120-1 Disponible https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6, accedido abril 6, 2020
Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41:145-151. https://doi.org/10.3760/cma.j
He, F, Deng, Y, Li, W. Coronavirus disease 2019: What we know? J Med Virol. 2020; 1- 7. https://doi.org/10.1002/jmv.25766.
D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic [published online ahead of print, 2020 Mar 20]. Liver Transpl. 2020;10.1002/lt.25756. https://doi.org/10.1002/lt.25756
Garbino J, Inoubli S, Mossdorf E, et al. Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection. AIDS. 2008;22(6):701-705. https://doi.org/10.1097/QAD.0b013e3282f470ac
Kenmoe S, Bigna JJ, Fatawou Modiyingi A, et al. Case fatality rate and viral aetiologies of acute respiratory tract infections in HIV positive and negative people in Africa: The VARIAFRICA-HIV systematic review and meta-analysis. J Clin Virol. 2019;117:96-102. https://doi.org/10.1016/j.jcv.2019.06.006
Bermejo JF, Muñoz-Fernandez MA. Severe acute respiratory syndrome, a pathological immune response to the new coronavirus--implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology. Viral Immunol. 2004;17(4):535-544. https://doi.org/10.1089/vim.2004.17.535
Tsang K, Seto WH. Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment. Curr Opin Investig Drugs. 2004;5(2):179-185.
Diao, Bo & Wang, Chenhui & Tan, Yingjun & Chen, Xiewan & Liu, Ying & Ning, Lifeng & Chen, Li & Li, Min & Liu, Yue-Ping & Wang, Gang & Yuan, Zilin & Feng, Zeqing & Wu, Yuzhang & Chen, Yongwen. (2020). Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). https://doi.org/10.3389/fimmu.2020.00827
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China [published online ahead of print, 2020 Mar 12]. Clin Infect Dis. 2020;ciaa248. https://doi.org/10.1093/cid/ciaa248
Joob B, Wiwanitkit V. SARS-CoV-2 and HIV [published online ahead of print, 2020 Mar 27]. J Med Virol. 2020;10.1002/jmv.25782. https://doi.org/10.1002/jmv.25782
Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China [published online ahead of print, 2020 Mar 11]. J Med Virol. 2020;10.1002/jmv.25732. https://doi.org/10.1002/jmv.25732
Guo, Wei and Ming, Fangzhao and Dong, Yu and Zhang, Qian and Zhang, Xiaoxia and Mo, Pingzheng and Feng, Yong and Liang, Ke, A Survey for COVID-19 Among HIV/AIDS Patients in Two Districts of Wuhan, China (3/4/2020). Available at SSRN: https://ssrn.com/abstract=3550029 or https://doi.org/10.2139/ssrn.3550029
Xiao C, Li X, Liu S, Sang Y, Gao SJ, Gao F. HIV-1 did not contribute to the 2019-nCoV genome. Emerg Microbes Infect. 2020;9(1):378-381. Published 2020 Feb 14. https://doi.org/10.1080/22221751.2020.1727299
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA. 2020;e201585. https://doi.org/10.1001/jama.2020.1585
Wu J, Liu J, Zhao X, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study [published online ahead of print, 2020 Feb 29]. Clin Infect Dis. 2020;ciaa199. https://doi.org/10.1093/cid/ciaa199
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Fenouillet E, Barbouche R, Jones IM. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. Antioxid Redox Signal. 2007;9(8):1009-1034. https://doi.org/10.1089/ars.2007.1639
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19 [published online ahead of print, 2020 Mar 28]. Int J Antimicrob Agents. 2020;105955. https://doi.org/10.1016/j.ijantimicag.2020.105955
Cockrell AS, Yount BL, Scobey T, Jensen K, Douglas M, Beall A, Tang XC, Marasco WA, Heise MT, Baric RS. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol 2016;2:16226. https://doi.org/10.1038/nmicrobiol.2016.226
Mulangu S, Dodd LE, Davey RT, Mbaya OT, Proschan M, Mukadi D et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381:2293-2303. https://doi.org/10.1056/NEJMoa1910993
Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256. https://doi.org/10.1136/thorax.2003.012658
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. Published 2020 Jan 10. https://doi.org/10.1038/s41467-019-13940-6
Ford, N., Vitoria, M., Rangaraj, A., Norris, S.L., Calmy, A. and Doherty, M. (2020), Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID‐19: initial assessment. J Intern AIDS Soc. Accepted Author Manuscript. https://doi.org/10.1002/jia2.25489
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 [published online ahead of print, 2020 Mar 18]. N Engl J Med. 2020;10.1056/NEJMoa2001282. https://doi.org/10.1056/NEJMoa2001282
Wen Xu, Si Chen. Academician Li Lanjuan suggests that two drugs should be written into the diagnosis and treatment plan, experts say that it should be carefully considered. Beijing News. 2020. Available at: http://www.bjnews.com.cn/news/2020/02/04/684375.html. Accessed March 11, 2020
Savarino A. Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza. J Clin Virol. 2005;34(3):170-178. https://doi.org/10.1016/j.jcv.2005.03.005
Fan J, Liu X, Pan W, Douglas MW, Bao S. Epidemiology of 2019 Novel Coronavirus Disease-19 in Gansu Province, China, 2020. Emerging Infect Dis. 2020;26(6). https://doi.org/10.3201/eid2606.200251
FDA Issues Safety Labeling Changes for Kaletra - Medscape - Apr 10, 2009
African countries move from COVID-19 readiness to response as many confirm cases [Internet] [Consultado 8 de abril de 2020] Disponible en: https://www.afro.who.int/health-topics/coronavirus-covid-19
UNAIDS data 2019 [Internet] [Consultado 8 de abril de 2020] Disponible en: https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data
Downloads
- Juan Carlos Alzate Angel, Marcela María Duque Molina, Héctor Iván García García, Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis , Colombia Medica: Vol. 48 No. 2 (2017)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use